Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 1039-1047

  Sylvester, Paul W ^a   Ayoub, Nehad M ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Akt; Breast cancer; PI3K; Tocotrienols; Vitamin E

Indexed keywords

ALPHA TOCOTRIENOL; CASPASE; CELECOXIB; DEATH RECEPTOR; EPIGALLOCATECHIN GALLATE; ERLOTINIB; FLICE INHIBITORY PROTEIN; GAMMA TOCOTRIENOL; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N (3 CHLOROPHENYL) 3 [3, 5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2, 3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RESVERATROL; TAMOXIFEN; TOCOPHEROL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RISK; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; IC 50; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOCOTRIENOLS; VITAMIN E;

EID: 84882783714     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990116     Document Type: Article

References (72)

1. Cancer Facts and Figures. American Cancer Society, 2011.
2. Nass, S.J.; Davidson, N.E. The biology of breast cancer. Hematol Oncol Clin North Am, 1999, 13, 311-332.
3. Biganzoli, L.; Minisini, A.; Aapro, M.; Di Leo, A. Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol, 2004, 16, 37-41.
4. Hernandez-Sotomayor, S.M.; Carpenter, G. Epidermal growth factor receptor: elements of intracellular communication. J Membr Biol, 1992, 128, 81-89.
5. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology, 2001, 61 Suppl 2, 1-13.
6. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001, 2, 127-137.
7. Normanno, N.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; De Luca, A.; Caponigro, F.; Salomon, D.S. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets, 2005, 6, 243-257.
8. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J, 2000, 19, 3159-3167.
9. Sliwkowski, M.X.; Schaefer, G.; Akita, R.W.; Lofgren, J.A.; Fitzpatrick, V.D.; Nuijens, A.; Fendly, B.M.; Cerione, R.A.; Vandlen, R.L.; Carraway, K.L., 3rd. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem, 1994, 269, 14661-14665.
10. Karunagaran, D.; Tzahar, E.; Beerli, R.R.; Chen, X.; Graus-Porta, D.; Ratzkin, B.J.; Seger, R.; Hynes, N.E.; Yarden, Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Embo J, 1996, 15, 254-264.
11. Kim, H.H.; Vijapurkar, U.; Hellyer, N.J.; Bravo, D.; Koland, J.G. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J, 1998, 334 (Pt 1), 189-195.
12. Witton, C.J.; Reeves, J.R.; Going, J.J.; Cooke, T.G.; Bartlett, J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 2003, 200, 290-297.
13. Nakshatri, H.; Bhat-Nakshatri, P.; Martin, D.A.; Goulet, R.J., Jr.; Sledge, G.W., Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol, 1997, 17, 3629-3639.
14. Sliva, D.; Rizzo, M.T.; English, D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem, 2002, 277, 3150-3157.
15. Vanhaesebroeck, B.; Aless, D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J, 2000, 346, 561-576.
16. Kandel, E.S.; Hay, N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res, 1999, 253, 210-229.
17. Baldwin, A.S., Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 1996, 14, 649-683.
18. Khwaja, A. Akt is more than just a Bad kinase. Nature, 1999, 401, 33-34.
19. Sakurai, H.; Chiba, H.; Miyoshi, H.; Sugita, T.; Toriumi, W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem, 1999, 274, 30353-30356.
20. Biswas, D.K.; Dai, S.C.; Cruz, A.; Weiser, B.; Graner, E.; Pardee, A.B. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci U S A, 2001, 98, 10386-10391.
21. Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol, 1998, 10, 262-267.
22. Holbro, T.; Beerli, R.R.; Maurer, F.; Koziczak, M.; Barbas, C.F., 3rd; Hynes, N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A, 2003, 100, 8933-8938.
23. Britten, C.D. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther, 2004, 3, 1335-1342.
24. Elnagar, A.Y.; Wali, V.B.; Sylvester, P.W.; El Sayed, K.A. Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion. Bioorg Med Chem, 2010, 18, 755-768.
25. Sylvester, P.W.; Theriault, A. Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr Top Nutraceutical Res, 2003, 1, 121-136.
26. Shah, S.; Sylvester, P.W. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med (Maywood), 2004, 229, 745-755.
27. Shah, S.J.; Sylvester, P.W. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. Exp Biol Med, 2005, 230, 235-241.
28. Packer, L. Protective role of vitamin E in biological systems. Am J Clin Nutr, 1991, 53, 1050S-1055S.
29. Elson, C.E. Tropical oils: nutritional and scientific issues. Crit Rev Food Sci Nutr, 1992, 31, 79-102.
30. Kimmick, G.G.; Bell, R.A.; Bostick, R.M. Vitamin E and breast cancer: a review. Nutr Cancer, 1997, 27, 109-117.
31. Goh, S.H.; Hew, N.F.; Norhanom, A.W.; Yadav, M. Inhibition of tumour promotion by various palm-oil tocotrienols. Int J Cancer, 1994, 57, 529-531.
32. Gould, M.N.; Haag, J.D.; Kennan, W.S.; Tanner, M.A.; Elson, C.E. A comparison of tocopherol and tocotrienol for the chemoprevention of chemically induced rat mammary tumors. Am J Clin Nutr, 1991, 53, 1068S-1070S.
33. Nesaretnam, K., Khor, H.T., Ganeson, J., Chong, Y.H., Sundram, K., and Gapor, A. The effects of vitamin E tocotrienols from palm oil on chemically induced mammary carcingenesis in female rats. Nutr. Res, 1992, 12, 879-892.
34. Zurinah, W., Ngah, W., Jarien, Z., San, M.M., Marzuki, A., Top, G.D., Shamaan, N.A., and Kadir, K.A. Effect of tocotrienols on hepatocarcinogenesis induced by 2-acetylaminofluorene in rats. Am. J. Clin. Nutr., 1991, 53, 1076S-1081S.
35. Nakayama, M.; Ju, H.R.; Sugano, M.; Hirose, N.; Ueki, T.; Doi, F.; Eynard, A.R. Effect of dietary fat and cholesterol on dimethylbenz [a]-anthracene-induced mammary tumorigenesis in Sprague-Dawley rats. Anticancer Res, 1993, 13, 691-698.
36. Cottrell, R.C. Introduction: nutritional aspects of palm oil. Am J Clin Nutr, 1991, 53, 989S-1009S.
37. Sundram, K.; Khor, H.T.; Ong, A.S.; Pathmanathan, R. Effect of dietary palm oils on mammary carcinogenesis in female rats induced by 7,12-dimethylbenz(a)anthracene. Cancer Res, 1989, 49, 1447-1451.
38. McIntyre, B.S.; Briski, K.P.; Gapor, A.; Sylvester, P.W. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med, 2000, 224, 292-301.
39. Sylvester, P.W. Targeting the PI3K/PDK/Akt signaling pathway in anticancer therapy. in. Trends in Signal Transduction Research, ed. M. Jennifer N. 2007: Nova Science Publishers, Inc. pp 173-190.
40. Waseem, N.H.; Lane, D.P. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci, 1990, 96 (Pt 1), 121-129.
41. Cross, D.A.; Alessi, D.R.; Cohen, P.; Andjelkovich, M.; Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 1995, 378, 785-789.
42. Jung, F.; Haendeler, J.; Goebel, C.; Zeiher, A.M.; Dimmeler, S. Growth factor-induced phosphoinositide 3-OH kinase/Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death. Cardiovascular Res, 2000, 48, 148-157.
43. Hutchinson, J.; Jin, J.; Cardiff, R.D.; Woodgett, J.R.; Muller, W.J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol, 2001, 21, 2203-2212.
44. Rohlff, C.; Glazer, R.I. Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell Signal, 1995, 7, 431-443.
45. Shah, S.; Gapor, A.; Sylvester, P.W. Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer, 2003, 45, 236-246.
46. Guthrie, N.; Gapor, A.; Chambers, A.F.; Carroll, K.K. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and-positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr, 1997, 127, 544S-548S.
47. Nesaretnam, K.; Dorasamy, S.; Darbre, P.D. Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. Int J Food Sci Nutr, 2000, 51 Suppl, S95-S103.
48. Hsieh, T.C.; Wu, J.M. Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. Int J Oncol, 2008, 33, 851-859.
49. Bachawal, S.V.; Wali, V.B.; Sylvester, P.W. Combined gammatocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res, 2010, 30, 429-437.
50. Bachawal, S.V.; Wali, V.B.; Sylvester, P.W. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer, 2010, 10, 84.
51. Shirode, A.B.; Sylvester, P.W. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother, 2010, 64, 327-332.
52. Wali, V.B.; Bachawal, S.V.; Sylvester, P.W. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood), 2009, 234, 639-650.
53. Wali, V.B.; Bachawal, S.V.; Sylvester, P.W. Suppression in Mevalonate Synthesis Mediates Antitumor Effects of Combined Statin and gamma-Tocotrienol Treatment. Lipids, 2009, 44, 925-934.
54. Wali, V.B.; Sylvester, P.W. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids, 2007, 42, 1113-1123.
55. Ayoub, N.M.; Bachawal, S.V.; Sylvester, P.W. gamma-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells. Cell Prolif, 2011, 44, 516-526.
56. Graaf, M.R.; Richel, D.J.; van Noorden, C.J.; Guchelaar, H.J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev, 2004, 30, 609-641.
57. Seeger, H.; Wallwiener, D.; Mueck, A.O. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes, 2003, 111, 47-48.
58. Shibata, M.A.; Ito, Y.; Morimoto, J.; Otsuki, Y.: Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis, 2004, 25, 1887-1898.
59. Campbell, M.J.; Esserman, L.J.; Zhou, Y.; Shoemaker, M.; Lobo, M.; Borman, E.; Baehner, F.; Kumar, A.S.; Adduci, K.; Marx, C.; Petricoin, E.F.; Liotta, L.A.; Winters, M.; Benz, S.; Benz, C.C. Breast cancer growth prevention by statins. Cancer Res, 2006, 66, 8707-8714.
60. Habenicht, A.J.; Glomset, J.A.; Ross, R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem, 1980, 255, 5134-5140.
61. Fairbanks, K.P.; Witte, L.D.; Goodman, D.S. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem, 1984, 259, 1546-1551.
62. Kaneko, I.; Hazama-Shimada, Y.; Endo, A. Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur J Biochem, 1978, 87, 313-321.
63. Quesney-Huneeus, V.; Galick, H.A.; Siperstein, M.D.; Erickson, S.K.; Spencer, T.A.; Nelson, J.A. The dual role of mevalonate in the cell cycle. J Biol Chem, 1983, 258, 378-385.
64. Maltese, W.A.; Defendini, R.; Green, R.A.; Sheridan, K.M.; Donley, D.K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest, 1985, 76, 1748-1754.
65. Staffa, J.A.; Chang, J.; Green, L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med, 2002, 346, 539-540.
66. Thibault, A.; Samid, D.; Tompkins, A.C.; Figg, W.D.; Cooper, M.R.; Hohl, R.J.; Trepel, J.; Liang, B.; Patronas, N.; Venzon, D.J.; Reed, E.; Myers, C.E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res, 1996, 2, 483-491.
67. Sylvester, P.W. Vitamin E and apoptosis. Vitam Horm, 2007, 76, 329-356.
68. Sylvester, P.W. Antiproliferative and apoptotic effects of tocotrienols on normal and neoplastic mammary epithelial cells. In. Tocotrienols: Vitamin E Beyond Tocopherols, ed. R.R. Watson and V.R. Preedy. 2009, Boca Raton: CRC Press. pp 119-140.
69. Matar, P.; Rojo, F.; Cassia, R.; Moreno-Bueno, G.; Di Cosimo, S.; Tabernero, J.; Guzman, M.; Rodriguez, S.; Arribas, J.; Palacios, J.; Baselga, J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res, 2004, 10, 6487-6501.
70. Reed, J.C. Dysregulation of apoptosis in cancer. J Clin Oncol, 1999, 17, 2941-2953.
71. Hughes, S.J.; Nambu, Y.; Soldes, O.S.; Hamstra, D.; Rehemtulla, A.; Iannettoni, M.D.; Orringer, M.B.; Beer, D.G. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res, 1997, 57, 5571-5578.
72. Yu, W.; Israel, K.; Liao, Q.Y.; Aldaz, C.M.; Sanders, B.G.; Kline, K. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res, 1999, 59, 953-961.